Company Filing History:
6 out of 1,829 
5 out of 53 
1 out of 101 Years Active: 2006-2012
Title: **Bama Santhanam: Innovator in Hepatitis C Treatment**
Introduction
Bama Santhanam, based in Bridgewater, NJ, is a prominent inventor recognized for his contributions to the field of biopharmaceuticals. With an impressive portfolio of six patents, Santhanam has significantly advanced the understanding and treatment of hepatitis C virus (HCV). His innovative work focuses on the development of peptide compounds that act as inhibitors for the NS3-serine protease enzyme, a crucial player in the viral lifecycle.
Latest Patents
Among his latest patents, Santhanam has developed novel compounds that exhibit HCV protease inhibitory activity. The inventions disclose methods for preparing such compounds and highlight pharmaceutical compositions that utilize these peptides for treating disorders linked to the HCV protease. His groundbreaking approach aims to provide effective treatments for individuals suffering from hepatitis C, enhancing the therapeutic options available in this critical area of medicine.
Career Highlights
Throughout his career, Bama Santhanam has held pivotal positions at reputable companies, including Schering Corporation and Dendreon Corporation. These experiences have allowed him to work on cutting-edge research and innovations in the pharmaceutical industry, particularly concerning antiviral therapies.
Collaborations
Santhanam's collaborative efforts with notable professionals, such as Viyyoor Moopil Girijavallabhan and F. George Njoroge, showcase his commitment to teamwork and innovation. Together with his colleagues, he has contributed to advancing science through shared knowledge and expertise, furthering the impact of his inventions.
Conclusion
In conclusion, Bama Santhanam's work in developing peptides as NS3-serine protease inhibitors reflects a significant stride in combating hepatitis C. His dedication to innovation and collaboration in the pharmaceutical sector continues to inspire many. With ongoing research and development, Santhanam is poised to make further contributions that may enhance the lives of countless individuals affected by hepatitis C.